肺腺癌患者的肺孢子菌肺炎：帕博利珠单抗的早期副作用
Pneumocystis pneumonia in patient with lung adenocarcinoma: early side effects from pembrolizumab.
作者信息
Hiba Zahi, Abdelmoughit Hosni, Zaynab Iraqi Houssaini, Hounaida Jerguigue, Rachida Latib, Youssef Omor
机构信息
Radiology Department, National Institute of Oncology, Ibn Sina Hospital, Mohammed V University, Rabat, Morocco.
出版信息
Radiol Case Rep. 2022 Aug 17;17(10):3979-3981. doi: 10.1016/j.radcr.2022.07.083. eCollection 2022 Oct.
Abstract
Immune check point inhibitor has made far-reaching changes in the management of lung adenocarcinoma improving drastically the prognosis. We present a case of a 50 years old women beneficiary of pembrolizumab who has suffered an acute pneumonitis diagnosed with CT imaging the days following the initiation of the drug. The occurrence of immune-related events such as pneumonitis complicates the use of immunotherapy and requires a well verse radiologist in the matter to diagnosis and helps prevent further aggravation.
摘要
免疫检查点抑制剂在肺腺癌的治疗管理方面带来了深远变革，极大地改善了预后。我们报告一例50岁女性患者，她是帕博利珠单抗的受益者，在开始使用该药物几天后，经CT成像诊断出患有急性肺炎。免疫相关事件如肺炎的发生使免疫治疗的应用变得复杂，这需要在该领域经验丰富的放射科医生进行诊断，并有助于防止病情进一步加重。
相似文献
1
Pneumocystis pneumonia in patient with lung adenocarcinoma: early side effects from pembrolizumab.
Radiol Case Rep. 2022 Aug 17;17(10):3979-3981. doi: 10.1016/j.radcr.2022.07.083. eCollection 2022 Oct.
2
[Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
Zhonghua Jie He He Hu Xi Za Zhi. 2017 Oct 12;40(10):736-743. doi: 10.3760/cma.j.issn.1001-0939.2017.10.006.
3
A potential mechanism of the onset of immune-related pneumonitis triggered by anti-PD-1 treatment in a patient with advanced adenocarcinoma lung cancer: case report.
BMC Pulm Med. 2021 Sep 14;21(1):291. doi: 10.1186/s12890-021-01649-6.
4
Late-onset programmed cell death protein-1 inhibitor-induced pneumonitis after cessation of nivolumab or pembrolizumab in patients with advanced non-small cell lung cancer: a case series.
Transl Lung Cancer Res. 2021 Mar;10(3):1576-1581. doi: 10.21037/tlcr-20-582.
5
[Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Beijing Da Xue Xue Bao Yi Xue Ban. 2022 Apr 18;54(2):369-375. doi: 10.19723/j.issn.1671-167X.2022.02.027.
6
Pembrolizumab-induced vitiligo in a patient with lung adenocarcinoma: A case report.
Br J Clin Pharmacol. 2021 Jun;87(6):2614-2618. doi: 10.1111/bcp.14663. Epub 2020 Dec 10.
7
Rapid temporal improvement of pembrolizumab-induced pneumonitis using the anti-TNF-α antibody infliximab.
Drug Discov Ther. 2019 Jul 22;13(3):164-167. doi: 10.5582/ddt.2019.01032. Epub 2019 Jun 28.
8
A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency.
Case Rep Oncol. 2021 Jan 11;14(1):1-7. doi: 10.1159/000508068. eCollection 2021 Jan-Apr.
9
Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
AJR Am J Roentgenol. 2021 Sep;217(3):613-622. doi: 10.2214/AJR.20.24758. Epub 2020 Dec 9.
10
Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
Curr Oncol. 2019 Aug;26(4):e571-e573. doi: 10.3747/co.26.4859. Epub 2019 Aug 1.
引用本文的文献
1
Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database.
Front Pharmacol. 2023 Mar 15;14:1129730. doi: 10.3389/fphar.2023.1129730. eCollection 2023.
2
Pneumocystis Pneumonia Infection Following the Initiation of Pembrolizumab Therapy for Lung Adenocarcinoma.
Intern Med. 2023 Nov 15;62(22):3381-3385. doi: 10.2169/internalmedicine.1163-22. Epub 2023 Mar 31.
本文引用的文献
1
Pneumocystis Infection in Two Patients Treated with Both Immune Checkpoint Inhibitor and Corticoids.
J Immunother Precis Oncol. 2020 Feb 10;3(1):27-30. doi: 10.4103/JIPO.JIPO_23_19. eCollection 2020 Feb.
2
Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management.
Radiographics. 2019 Nov-Dec;39(7):1923-1937. doi: 10.1148/rg.2019190036. Epub 2019 Oct 4.
3
Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases.
Clin Lung Cancer. 2019 May;20(3):e247-e250. doi: 10.1016/j.cllc.2018.12.006. Epub 2018 Dec 19.
4
Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: A case-control study.
Cancer Med. 2018 Aug;7(8):4115-4120. doi: 10.1002/cam4.1579. Epub 2018 May 23.
5
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.
Eur Respir J. 2017 Aug 10;50(2). doi: 10.1183/13993003.00050-2017. Print 2017 Aug.
6
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
J Clin Oncol. 2017 Mar;35(7):709-717. doi: 10.1200/JCO.2016.68.2005. Epub 2016 Sep 30.
7
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.
JAMA Oncol. 2016 Dec 1;2(12):1607-1616. doi: 10.1001/jamaoncol.2016.2453.
8
Nivolumab-induced organizing pneumonia in a melanoma patient.
Jpn J Clin Oncol. 2016 Mar;46(3):270-2. doi: 10.1093/jjco/hyv199. Epub 2016 Jan 12.
9
Pembrolizumab for the treatment of non-small-cell lung cancer.
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
10
Update on the diagnosis and treatment of Pneumocystis pneumonia.
Ther Adv Respir Dis. 2011 Feb;5(1):41-59. doi: 10.1177/1753465810380102. Epub 2010 Aug 24.
Zotero 插件